Back to News
Market Impact: 0.48
Immunovant To Stop Development Of IMVT-1402 In Cutaneous Lupus Erythematosus
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Immunovant reported that Period 1 of its proof-of-concept trial for IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint. The failed primary endpoint is a material clinical-development setback that could pressure Immunovant shares and increase uncertainty around the program's future development path.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.62
Ticker Sentiment
IMVT-0.85
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- These funds tout hefty income tied to the tech trade – if you’re willing to deal with the complexity
- Street Calls of The Week
- Meta’s $25 Billion Bond Sale Highlights Shifting Landscape for Tech Debt
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Coffee giant Dutch Bros made all of its executives, including the CEO, do a two-week bootcamp where they learned how to pour drinks and run stores